CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. RESEARCH METHODOLOGY

1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.1.1. Rising geriatric population
3.4.1.2. Increasing prevalence of chronic disorders
3.4.1.3. Rise in adoption of third-generation delivery systems

3.4.2. Restraints

3.4.2.1. Side-effects of the systems

3.4.3. Opportunities

3.4.3.1. Emerging nations

CHAPTER 4 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE OF DELIVERY SYSTEM

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PASSIVE DELIVERY SYSTEM

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.2.3.1. Matrix delivery system

4.2.3.1.1. Market size and forecast

4.2.3.2. Reservoir delivery system

4.2.3.2.1. Market size and forecast

4.3. ACTIVE DELIVERY SYSTEM

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.3.3.1. Structure-based drug delivery system

4.3.3.1.1. Market size and forecast

4.3.3.2. Electrically-based drug delivery system

4.3.3.2.1. Market size and forecast
4.3.3.2.2. Iontophoresis

4.3.3.2.2.1. Market size and forecast

4.3.3.2.3. Electroporation

4.3.3.2.3.1. Market size and forecast

4.3.3.2.4. Sonophoresis

4.3.3.2.4.1. Market size and forecast

4.3.3.3. Other

4.3.3.3.1. Market size and forecast

CHAPTER 5 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ANALGESICS

5.2.1. Market size and forecast

5.3. HORMONE REPLACEMENT THERAPY

5.3.1. Market size and forecast

5.4. HYPERTENSION

5.4.1. Market size and forecast

5.5. MOTION SICKNESS

5.5.1. Market size and forecast

5.6. SMOKING CESSATION

5.6.1. Market size and forecast

5.7. OTHERS

5.7.1. Market size and forecast

CHAPTER 6 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Growth factors and opportunities
6.2.3. Market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Growth factors and opportunities
6.3.3. Market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Growth factors and opportunities
6.4.3. Market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Growth factors and opportunities
6.5.3. Market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. ACRUX LIMITED

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments
7.1.6. Strategy share (%)

7.2. BAYER AG

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.2.6. Strategy share (%)

7.3. BOEHRINGER INGELHEIM GMBH

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments
7.3.6. Strategy share (%)

7.4. BRISTOL-MYERS SQUIBB COMPANY

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.4.5. Key strategic moves and developments
7.4.6. Strategy share (%)

7.5. ECHO THERAPEUTICS, INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.5.6. Strategy share (%)

7.6. ENDO PHARMACEUTICALS INC.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments
7.6.6. Strategy share (%)

7.7. GLAXOSMITHKLINE PLC

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments
7.7.6. Strategy share (%)

7.8. JOHNSON & JOHNSON

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments
7.8.6. Strategy share (%)

7.9. MYLAN N.V.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments
7.9.6. Strategy share (%)

7.10. NOVARTIS AG

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments
7.10.6. Strategy share (%)